Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes
Clinical and Experimental Immunology · 21.01.2025 · 219 (1)
DOI: 10.1093/cei/uxaf010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 18.02.2025. Verfasst von Cecilie Oelvang Madsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Immunotherapy, Adoptive, Melanoma, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Danish Cancer Society, The Danish Council for Independent Research, Capital Region of Denmark Research Foundation.
Abstract (Originalsprache)
Adoptive cell therapy (ACT) with ex-vivo expanded tumor-infiltrating lymphocytes (TILs, TIL-ACT) has shown clinical efficacy in a significant proportion of patients with metastatic melanoma. To further target TIL-ACT toward responsive patients, identifying predictive biomarkers and understanding broader immune dynamics remain critical. This study investigated the peripheral blood immune landscape in 47 patients with metastatic melanoma undergoing TIL-ACT, assessing antitumor reactivity and peripheral immune cell profiles before and after treatment. Responders displayed increased frequency of circulating tumor-reactive cells post-treatment, and higher baseline levels of activated CD57-expressing T cells, serving as potential biomarkers of response. In contrast, persistent high serum levels of interleukin (IL)-6 and IL-8, higher frequencies of CD38-expressing T cells, and regulatory T cells (Tregs) post-treatment, correlated with unfavorable outcomes. These findings contribute to understanding the peripheral immune landscape associated with response to TIL-ACT, offering valuable insights into predictive biomarkers and mechanisms to improve patient selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
ORCID-Profile: Cecilie Oelvang Madsen
Förderung
- Danish Cancer Society
- The Danish Council for Independent Research
- Capital Region of Denmark Research Foundation
Zitieren
APA
Madsen, C. O., Velasco Santiago, M., Martinenaite, E., Holz Borch, T., Donia, M., Svane, I. M., & Hansen, M. (2025). Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes. Clinical and Experimental Immunology, 219(1). https://doi.org/10.1093/cei/uxaf010
Vancouver
Madsen CO, Velasco Santiago M, Martinenaite E, Holz Borch T, Donia M, Svane IM, et al. Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes. Clinical and Experimental Immunology. 2025;219(1). doi:10.1093/cei/uxaf010
BibTeX
@article{Madsen2025,
author = {Madsen, Cecilie Oelvang and Velasco Santiago, Marta and Martinenaite, Evelina and Holz Borch, Troels and Donia, Marco and Svane, Inge Marie and Hansen, Morten},
title = {Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes},
journal = {Clinical and Experimental Immunology},
year = {2025},
volume = {219},
number = {1},
doi = {10.1093/cei/uxaf010}
}
EUVIMED